Cyclacel Pharma (CYCC) Reports Q1 Loss Per Share of $0.19
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Cyclacel Pharmaceuticals Reports First Quarter 2015 Financial Results
May 12, 2015 4:05 PM EDT-- Approximately 20% of prespecified events remaining in SEAMLESS before study unblinding -- -- Received FDA clearance for the first-in-human Phase 1 study of CYC065 CDK inhibitor -- -- Conference Call Scheduled May 12, 2015 at 4:30 p.m. Eastern Time --
BERKELEY HEIGHTS, N.J., May 12, 2015 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of... More
